Pricing Log in Create free account

Anavex Life Sciences Corp. (AVXL) vs Coherus Oncology, Inc. (CHRS)

Anavex Life Sciences Corp. and Coherus Oncology, Inc. are both Biotechnology companies. Anavex Life Sciences Corp. and Coherus Oncology, Inc. are of similar size ($98.3M and $90.0M). Anavex Life Sciences Corp. has the higher net margin (0.00% vs −253.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Anavex Life Sciences Corp. leads on 10 and Coherus Oncology, Inc. on 3.

Valuation

Metric AVXL CHRS Biotechnology median
P/E n/m n/m 11.58
P/S n/m 1.70 9.61
P/B 0.87 3.62 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA 1.16 n/m 0.72
EV/Sales n/m 4.39 9.43
Earnings yield (14.15%) (165.05%) (32.28%)
Free cash flow yield (29.82%) (191.02%) (22.27%)

Profitability

Metric AVXL CHRS Biotechnology median
Gross margin — 69.81% 68.81%
Operating margin 0.00% (275.94%) 0.00%
Net margin 0.00% (253.43%) 0.00%
Free cash flow margin 0.00% (323.85%) 0.00%
Return on equity (12.80%) (240.54%) (50.30%)
Return on assets (11.70%) (39.54%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVXL CHRS Biotechnology median
Revenue growth (TTM) — 44.36% 6.78%
EPS growth (last fiscal year) (3.85%) 472.00% 29.88%
Revenue growth, 5-year CAGR — (38.41%) 9.75%
Net income growth, 5-year CAGR 0.00% 4.91% 0.00%

Health

Metric AVXL CHRS Biotechnology median
Debt to equity 0.00 2.08 0.00
Current ratio 15.62 1.51 4.74
Net debt to EBITDA 2.00 0.76 1.01

Dividend

Metric AVXL CHRS Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric AVXL CHRS Biotechnology median
Market cap 98.26m 90.02m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack